Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1971 1
1981 1
1983 1
1986 2
1987 2
1988 1
1990 3
1991 4
1992 4
1993 3
1994 1
1995 5
1996 3
1997 3
1998 6
1999 6
2000 4
2001 4
2002 6
2003 7
2004 4
2005 6
2006 10
2007 7
2008 13
2009 8
2010 6
2011 5
2012 12
2013 5
2014 2
2015 13
2016 10
2017 23
2018 15
2019 39
2020 54
2021 54
2022 64
2023 47
2024 31
2025 15

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

435 results

Results by year

Filters applied: . Clear all
Page 1
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
Richardson PG, Oriol A, Beksac M, Liberati AM, Galli M, Schjesvold F, Lindsay J, Weisel K, White D, Facon T, San Miguel J, Sunami K, O'Gorman P, Sonneveld P, Robak P, Semochkin S, Schey S, Yu X, Doerr T, Bensmaine A, Biyukov T, Peluso T, Zaki M, Anderson K, Dimopoulos M; OPTIMISMM trial investigators. Richardson PG, et al. Lancet Oncol. 2019 Jun;20(6):781-794. doi: 10.1016/S1470-2045(19)30152-4. Epub 2019 May 13. Lancet Oncol. 2019. PMID: 31097405 Clinical Trial.
Prednisone vs high-dose dexamethasone in newly diagnosed adult primary immune thrombocytopenia: a randomized trial.
Mazzucconi MG, Rodeghiero F, Avvisati G, De Stefano V, Gugliotta L, Ruggeri M, Vianelli N, Fazi P, Paoloni F, Sargentini V, Baldacci E, Ferretti A, Martino B, Vincelli ID, Carli G, Fortuna S, Di Ianni M, Ranalli P, Palandri F, Polverelli N, Lugli E, Rivolti E, Patriarca A, Rago A, D'Adda M, Gentile M, Siragusa S, Sibilla S, Carella AM, Rossi E, Battistini R, Zaja F, Bocchia M, Di Renzo N, Musto P, Crugnola M, Giuffrida AC, Krampera M, Tafuri A, Santoro C. Mazzucconi MG, et al. Among authors: tafuri a. Blood Adv. 2024 Mar 26;8(6):1529-1540. doi: 10.1182/bloodadvances.2023010975. Blood Adv. 2024. PMID: 38231017 Free PMC article. Clinical Trial.
Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission.
Wei AH, Döhner H, Pocock C, Montesinos P, Afanasyev B, Dombret H, Ravandi F, Sayar H, Jang JH, Porkka K, Selleslag D, Sandhu I, Turgut M, Giai V, Ofran Y, Kizil Çakar M, Botelho de Sousa A, Rybka J, Frairia C, Borin L, Beltrami G, Čermák J, Ossenkoppele GJ, La Torre I, Skikne B, Kumar K, Dong Q, Beach CL, Roboz GJ; QUAZAR AML-001 Trial Investigators. Wei AH, et al. N Engl J Med. 2020 Dec 24;383(26):2526-2537. doi: 10.1056/NEJMoa2004444. N Engl J Med. 2020. PMID: 33369355 Free article. Clinical Trial.
Cardiovascular events and intensity of treatment in polycythemia vera.
Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, De Stefano V, Elli E, Iurlo A, Latagliata R, Lunghi F, Lunghi M, Marfisi RM, Musto P, Masciulli A, Musolino C, Cascavilla N, Quarta G, Randi ML, Rapezzi D, Ruggeri M, Rumi E, Scortechini AR, Santini S, Scarano M, Siragusa S, Spadea A, Tieghi A, Angelucci E, Visani G, Vannucchi AM, Barbui T; CYTO-PV Collaborative Group. Marchioli R, et al. N Engl J Med. 2013 Jan 3;368(1):22-33. doi: 10.1056/NEJMoa1208500. Epub 2012 Dec 8. N Engl J Med. 2013. PMID: 23216616 Free article. Clinical Trial.
Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial.
Daver NG, Dail M, Garcia JS, Jonas BA, Yee KWL, Kelly KR, Vey N, Assouline S, Roboz GJ, Paolini S, Pollyea DA, Tafuri A, Brandwein JM, Pigneux A, Powell BL, Fenaux P, Olin RL, Visani G, Martinelli G, Onishi M, Wang J, Huang W, Green C, Ott MG, Hong WJ, Konopleva MY, Andreeff M. Daver NG, et al. Among authors: tafuri a. Blood. 2023 Mar 16;141(11):1265-1276. doi: 10.1182/blood.2022016362. Blood. 2023. PMID: 36265087 Free PMC article. Clinical Trial.
10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial.
Lübbert M, Wijermans PW, Kicinski M, Chantepie S, Van der Velden WJFM, Noppeney R, Griškevičius L, Neubauer A, Crysandt M, Vrhovac R, Luppi M, Fuhrmann S, Audisio E, Candoni A, Legrand O, Foà R, Gaidano G, van Lammeren-Venema D, Posthuma EFM, Hoogendoorn M, Giraut A, Stevens-Kroef M, Jansen JH, de Graaf AO, Efficace F, Ammatuna E, Vilque JP, Wäsch R, Becker H, Blijlevens N, Dührsen U, Baron F, Suciu S, Amadori S, Venditti A, Huls G; EORTC Leukemia Group, GIMEMA, and German MDS Study Group. Lübbert M, et al. Lancet Haematol. 2023 Nov;10(11):e879-e889. doi: 10.1016/S2352-3026(23)00273-9. Lancet Haematol. 2023. PMID: 37914482 Free article. Clinical Trial.
Dosing and clinical outcomes of ruxolitinib in patients with myelofibrosis in a real-world setting: Interim results of the Italian observational study (ROMEI).
Breccia M, Palandri F, Martelli M, Mendicino F, Malato A, Palumbo GA, Sibilla S, Di Renzo N, Abruzzese E, Siragusa S, Crugnola M, Selleri C, Pane F, Sportoletti P, Martino B, Impera S, Ricco A, Langella M, Ditonno P, Carli G, Itri F, Liberati AM, Urbano T, Tafuri A, Polizzi V, Pastore D, Morsia E, Benevolo G, Micucci G, Farina G, Bonifacio M, Elli EM, Gardellini A, De Stefano V, Caocci G, Falcone AP, Vallisa D, Brociner M, Tiribelli M, Binotto G, Pocali B, Cavazzini F, Tomassetti S, Lunghi F, Di Ianni M, Allegra A, Anaclerio B, Mazzotta S, Orofino N, Gherlinzoni F, Castiglioni C, Landoni M, Valsecchi D, Magnoli M, Guglielmelli P, Passamonti F. Breccia M, et al. Among authors: tafuri a. Cancer. 2025 Apr 1;131(7):e35801. doi: 10.1002/cncr.35801. Cancer. 2025. PMID: 40111826 Free PMC article.
A Double-Blind, Placebo-Controlled Parallel Group Study to Evaluate the Effect of a Single Oral Dose of 5-HT1A Antagonist GSK958108 on Ejaculation Latency Time in Male Patients Suffering From Premature Ejaculation.
Migliorini F, Tafuri A, Bettica P, Ziviani L, Lund J, Poggesi I, Marcer A, Cacciamani GE, Lorenzo-Gomez MF, Porcaro AB, Antonelli A, Milleri S. Migliorini F, et al. Among authors: tafuri a. J Sex Med. 2021 Jan;18(1):63-71. doi: 10.1016/j.jsxm.2020.09.012. Epub 2020 Nov 20. J Sex Med. 2021. PMID: 33223426 Clinical Trial.
Reply by Authors.
Oishi M, Gill IS, Tafuri A, Shakir A, Cacciamani GE, Iwata T, Iwata A, Ashrafi A, Park D, Cai J, Desai M, Ukimura O, Bahn DK, Abreu AL. Oishi M, et al. Among authors: tafuri a. J Urol. 2020 Jul;204(1):158-159. doi: 10.1097/JU.0000000000001009. Epub 2020 Mar 6. J Urol. 2020. PMID: 32149568 No abstract available.
Reply by Authors.
Oishi M, Gill IS, Tafuri A, Shakir A, Cacciamani GE, Iwata T, Iwata A, Ashrafi A, Park D, Cai J, Desai M, Ukimura O, Bahn DK, Abreu AL. Oishi M, et al. Among authors: tafuri a. J Urol. 2019 Dec;202(6):1198. doi: 10.1097/01.JU.0000582672.51608.a4. Epub 2019 Sep 16. J Urol. 2019. PMID: 31524574 No abstract available.
435 results